Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study
Autor: | Maria Chiara Tisi, Michelina Dargenio, for Sorveglianza Epidemiologica Infezioni nelle Emopatie, Federica Lessi, Francesca Farina, Livio Pagano, Andrea Visentin, Angelica Spolzino, Luca Laurenti, Davide Facchinelli, M. Picardi, Gianpaolo Nadali, Chiara Cattaneo, Fabio Trastulli, Luisa Verga, Francesco Marchesi, Anna Candoni, Alessandro Busca, Lucia Prezioso, Gessica Marchesini, Rosa Fanci |
---|---|
Přispěvatelé: | Marchesini, G., Nadali, G., Facchinelli, D., Candoni, A., Cattaneo, C., Laurenti, L., Fanci, R., Farina, F., Lessi, F., Visentin, A., Marchesi, F., Prezioso, L., Spolzino, A., Tisi, M. C., Trastulli, F., Picardi, M., Verga, L., Dargenio, M., Busca, A., Pagano, L. |
Rok vydání: | 2020 |
Předmět: |
Male
medicine.medical_treatment infections lymphoproliferative diseases targeted therapy Targeted therapy chemistry.chemical_compound 0302 clinical medicine Piperidines Risk Factors Agammaglobulinaemia Tyrosine Kinase Medicine Molecular Targeted Therapy Enzyme Inhibitors Aged 80 and over Bacterial Infections Hematology Middle Aged Clinical Practice Italy Virus Diseases 030220 oncology & carcinogenesis Ibrutinib Female Idelalisib Research Paper medicine.medical_specialty Lymphoproliferative disorders Opportunistic Infections 03 medical and health sciences Internal medicine Humans In patient Protein Kinase Inhibitors lymphoproliferative disease Aged Quinazolinones Retrospective Studies business.industry Adenine Retrospective cohort study medicine.disease Haematological Malignancy – Clinical Lymphoproliferative Disorders infection Settore MED/15 - MALATTIE DEL SANGUE chemistry Purines Case-Control Studies Frequent infections business Invasive Fungal Infections 030215 immunology |
Zdroj: | British Journal of Haematology |
ISSN: | 1365-2141 0007-1048 |
Popis: | Summary We describe the opportunistic infections occurring in 362 patients with lymphoproliferative disorders treated with ibrutinib and idelalisib in clinical practice. Overall, 108 of 362 patients (29·8%) developed infections, for a total of 152 events. Clinically defined infections (CDI) were 49·3% (75/152) and microbiologically defined infections (MDI) were 50·7% (77/152). Among 250 patients treated with ibrutinib, 28·8% (72/250) experienced one or more infections, for a total of 104 episodes. MDI were 49% (51/104). Bacterial infections were 66·7% (34/51), viral 19·6% (10/51) and invasive fungal diseases (IFD) 13·7% (7/51). Among the 112 patients treated with idelalisib, 32·1% (36/112) experienced one or more infections, for a total of 48 episodes. MDI were 54·2% (26/48). Bacterial infections were 34·6% (9/26), viral 61·5% (16/26) and IFD 3·8% (1/26). With ibrutinib, the rate of bacterial infections was significantly higher compared to idelalisib (66·7% vs. 34·6%; P = 0·007), while viral infections were most frequent in idelalisib (61·5% vs. 19·6%; P |
Databáze: | OpenAIRE |
Externí odkaz: |